Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 3 years
- Director since
- 2023
3 years of board service in total across 1 board, counting each seat separately. Longest: Bolt Biotherapeutics Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Bolt Biotherapeutics Inc. June 12, 202399.5%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 30, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −108,145 | $0.86 | $93,005 |
| Nov 30, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −14,934 | $0.86 | $12,843 |
| Nov 29, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −22,674 | $0.91 | $20,633 |
| Nov 29, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −3,131 | $0.91 | $2,849 |
| Nov 21, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −1,707 | $0.90 | $1,536 |
| Nov 21, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −236 | $0.90 | $212 |
| Nov 20, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −27,465 | $0.92 | $25,268 |
| Nov 20, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −3,792 | $0.92 | $3,489 |
| Nov 17, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −8,211 | $0.93 | $7,636 |
| Nov 17, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −1,134 | $0.93 | $1,055 |
| Nov 16, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −7,531 | $0.96 | $7,230 |
| Nov 16, 2023 | Bolt Biotherapeutics Inc. | Open-market sale | −1,040 | $0.96 | $998 |
Questions about Edgar Engleman
What boards is Edgar Engleman on?
Edgar Engleman sits on the board of Bolt Biotherapeutics Inc.
How long has Edgar Engleman served on boards?
Our records show at least 3 years of board service across 1 board, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.